Page last updated: 2024-11-05

ticlopidine and Hyperlipoproteinemia Type IV

ticlopidine has been researched along with Hyperlipoproteinemia Type IV in 1 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Hyperlipoproteinemia Type IV: A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
del Rey Moreno, J1
López Cortés, LF1
Gómez Mateos, JM1
Lozano de León, F1

Other Studies

1 other study available for ticlopidine and Hyperlipoproteinemia Type IV

ArticleYear
[Agranulocytosis caused by ticlopidine].
    Neurologia (Barcelona, Spain), 1992, Volume: 7, Issue:5

    Topics: Agranulocytosis; Humans; Hyperlipoproteinemia Type IV; Male; Middle Aged; Ticlopidine

1992